Prevention strategies for chemotherapy-induced hand–foot syndrome: a systematic review and meta-analysis of prospective randomised trials
- 26 January 2014
- journal article
- research article
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 22 (6) , 1585-1593
Abstract
Hand–foot syndrome (HSF) is a distinctive adverse event relatively frequent to some chemotherapeutic agents as capecitabine, pegylated liposomal doxorubicin, sorafenib and other tyrosine-kinase inhibitors. Since the prevention of HFS would be crucial to avoid treatment interruptions and delays, many studies have been conducted with this purpose. The aim of this systematic review and meta-analysis was to analyze the clinical efficacy of prevention strategies for HFS, through a wide search of electronic databases as well as congress abstracts. The endpoints evaluated were the dichotomic data for mild (Grade 1), moderate to severe (Grades 2 to 3) and all-grade HFS. Meta-analysis was calculated through RevMan v5.1 software. Amongst 295 studies identified, only ten met the inclusion criteria. Celecoxib prevented both moderate to severe (odds ratio [OR] 0.39, 95 % confidence interval [CI] 0.20–0.73, P = 0.003) and all-grade HFS (OR 0.47, 95 % CI 0.29–0.78, P = 0.003), whereas pyridoxine and topical urea/lactic acid formulations failed to prove efficacy. There were no proven benefits in mild HFS. The use of topical antiperspirant has not been shown to improve results, according to a single trial. From all available possibilities for the prevention of HFS, celecoxib appears to be the most promising, with statistically significant results. Larger, multicentric studies are required to reinforce this finding.Keywords
This publication has 40 references indexed in Scilit:
- Unilateral Hand-Foot Syndrome: Does It Take Sides? Case Report and Literature ReviewClinical Colorectal Cancer, 2012
- HFS-14, a Specific Quality of Life Scale Developed for Patients Suffering from Hand–Foot SyndromeThe Oncologist, 2011
- Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trialThe Lancet, 2011
- Placebo-Controlled Trial to Determine the Effectiveness of a Urea/Lactic Acid–Based Topical Keratolytic Agent for Prevention of Capecitabine-Induced Hand-Foot Syndrome: North Central Cancer Treatment Group Study N05C5Journal of Clinical Oncology, 2010
- The effect of COX-2 inhibitor on capecitabine-induced hand–foot syndrome in patients with stage II/III colorectal cancer: a phase II randomized prospective studyJournal of Cancer Research and Clinical Oncology, 2010
- A double‐blind, randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin‐related hand‐foot syndrome in gynecologic oncology patientsCancer, 2010
- Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experienceBritish Journal of Cancer, 2009
- Pegylated liposomal doxorubicin-associated hand–foot syndrome: Recommendations of an international panel of expertsEuropean Journal of Cancer, 2008
- Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome?Annals of Oncology, 2005
- CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatmentSeminars in Radiation Oncology, 2003